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(57) ABSTRACT 
The present invention relates to a composition of matter 
for the time-dependent liberation of therapeutic agents. 
This composition of matter comprises a polymeric slab 
and a homogeneously dispersed enzyme which de 
grades the polymeric slab in the presence of moisture. 
The therapeutic agent is physically entrapped in the 
polymeric slab by inclusion during polymerization to 
form the polymeric slab or by mixture of the therapeu 
tic agent with a liquid form of the polymeric slab and 
conversion of the liquid to a solid form. The therapeutic 
agent is not chemically bound to the polymer, and thus 
release of the agent is immediately effected upon the 
specific moisture-activated enzymatic degradation of 
the polymer slab. Moisture for enzymatic activation is 
provided by the biological surface on which the slab is 
emplaced, such as the dermal surface. The composition 
comprises a polymer such as poly (DL-lactide) and an 
enzyme such as proteinase K together with chlorphen 
iramine maleate as the therapeutic agent. 
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DELIVERY OF THERAPEUTICAGENTS 
The present application is a continuation-in-part of 
U.S. patent application Ser. No. 06/918,819, filed Oct. 
14, 1986, now abandoned, upon which priority is 
claimed. 
FIELD OF THE INVENTION 
The present invention relates to the delivery of thera 
peutic agents and a system to control and enhance re 
lease of therapeutic agents from polymeric reservoirs. 
The unique utility of the present invention partially 
resides in the combination of a polymeric substance 
containing a therapeutic agent with a moisture 
activated enzyme capable of degrading the polymeric 
substance to facilitate the liberation of the therapeutic 
agent. 
BACKGROUND OF THE INVENTION 
Polymeric materials have been used for medical and 
surgical applications for 30 to 40 years and these appli 
cations often involved the use of the polymers in inti 
mate contact with living tissues (Williams, Journal of 
Materials Science, (1982), 17:1233-1246). It has been 
stated that "the development of polymers containing 
hydrolytically or enzymatically labile bonds has been 
an ongoing activity for a very long time, principally in 
connection with a search for improved absorbable su 
tures. Although these sutures were originally derived 
almost exclusively from various forms of collagen and 
evolved to the modern day catgut, there has also been 
an increasing emphasis on developing synthetic materi 
als that would hydrolyze to natural metabolites. 
As a result of these efforts, two materials emerged, 
poly(lactic acid) and poly(glycolic acid) (Heller, mate 
rial presented at the Massachusetts Institute of Technol 
ogy Special Summer Program held Jul. 19 through Jul. 
23, 1982). Since the first disclosure of the use of a syn 
thetic biodegradable polymer for the systemic delivery 
of a therapeutic agent reported by Yolles, et al. (1970), 
a large body of literature has evolved which describes 
therapeutic agent release from bioerodible polymers. 
Three types of therapeutic agent release have been 
described which can occur from bioerodible polymers 
based on the mechanism of polymer erosion. These 
three types are designated as Type I, Type II and Type 
III erosion. 
A Type I erosion system is composed of a water-solu 
ble polymer which has been insolubilized by hydrolyti 
cally unstable crosslinks. The three-dimensional net 
work of the system remains intact (insoluble) and can 
only swell to the extent allowed by the crosslink density 
when first placed in an aqueous environment. However, 
on prolonged contact with an aqueous environment, the 
crosslinks, which are hydrolytically labile, begin to 
cleave, the crosslink density decreases and the network 
will swell to the point where the majority of the cross 
links are broken and the matrix will dissolve. This type 
of system is very useful for the release of agents which 
have a very low water solubility and for macromole 
cules that can be physically entangled in the matrix. In 
this last case, the agents cannot diffuse out even though 
they are very water soluble. As a result, escape and 
dissolution of the agents can only take place after 
enough crosslinks have been cleaved to allow disentan 













A Type II erosion system is composed of water 
insoluble polymeric material which can be solubilized 
by hydrolysis, ionization, or protonation of a pendant 
group. Since the solubilization does not involve back 
bone cleavage, there is no significant change in molecu 
lar weight of the polymer as it is solubilized. Due to this 
fact, this type of system is useful for topical applications 
where the elimination of high molecular weight, water 
soluble macromolecules is not a problem. This is not the 
case where this type of system is used internally as 
implant material because, in this situation, high molecu 
lar weight materials can cause elimination problems. 
The major use of this type of system has been in the field 
of enteric coatings where these coatings are designed to 
be soluble at specific pH's of the gastrointestinal tract. 
A Type III erosion system is composed of hydropho 
bic polymers which are converted to small, water-solu 
ble molecules by cleavage of hydrolytically labile bonds 
in the polymer backbone. In the past, the principle use 
of this type of system has been for the systemic adminis 
tration of therapeutic agents from subcutaneous, intra 
muscular, or intraperitoneal implantation sites where 
the method of therapeutic agent delivery necessitates 
the use of polymers whose degradation products are 
nontoxic. Heller (Heller, material presented at the Mas 
sachusetts Institute of Technology Special Summer 
Program held Jul. 19 through Jul. 23, 1982)) stated that 
systems based on this type of erosion are being devel 
oped along four parallel approaches. These include: (a) 
diffusional systems in which the rate-limiting barrier 
membrane will ultimately erode; (b) bioerodible micro 
capsules; (c) monolithic devices containing dispersed or 
dissolved therapeutic agent; and (d) bioerodible poly 
mers containing therapeutic agents chemically bound to 
the polymer backbone. 
This last class of bioerodable system was described by 
Kopachek et al. (1983, Prog. Polym. Sci, 9:1-58) in an 
article reviewing the biodegradation of various biomed 
ical polymers. The author reviews the work of others in 
the field who use polylactic acid as the polymer of 
choice. The rate of polymer degradation and drug re 
lease is controlled through chemical modification of the 
particular polymer(s) used as well as the ratio of in 
cluded polymers one to another. However, the use of an 
extrinsic enzyme in or on the polymer device was not 
introduced to further control or enhance a linear rate of 
drug release from the polymer. While erosion rate mod 
ifiers, such as those disclosed by Schmidt et al. (U.S. 
Pat. No. 4,346,709), have been used in conjunction with 
polymeric devices to decrease the rate of drug delivery, 
the inclusion of a "modifier', for example an enzyme, 
has not been proposed to enhance the rate of drug re 
lease. 
Others in the art have discussed the ability of natu 
rally occurring enzymes to degrade polymeric sub 
stances (Williams, D. F. (1980), Eng. Med., 10:5-7). For 
example, Williams described the enzymatic degradation 
of polylactic acid by various enzymes, including brome 
lain, esterase, ficin, lactate dehydrogenase, pronase and 
proteinase K (Id. at 6). However, the inclusion of a 
therapeutic agent in such a system was not addressed. 
The inclusion of a therapeutic agent in a polymeric 
substrate together with an enzyme was later examined 
by Langer and co-workers, but only in reference to the 
cleavage of drug-polymer bonds in a "pendant' chain 
system (Langer, A. (1980) Chen. Eng. Commun., 
6:1-48). This system required that the cleavage of the 
drug from the polymer backbone be the rate-limiting 
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step in order that a constant release of the drug from the 
polymer be achieved (Id. at 33). Such would require 
that the rate of diffusion of the enzyme and the rate of 
diffusion of the drug be faster than the rate of drug 
polymer cleavage by the enzyme (Id.). This particular 
system limited the use of therapeutic agents to those 
"bindable' (i.e., those with particular conformational 
and/or structural characteristics) to a polymeric sub 
strate. The use of enzymes in conjunction with unbound 
therapeutic agents in a polymeric slab, however, re 
mained unexplored. 
The present invention comprises a type III erosion 
system. However, the therapeutic agent of the present 
invention is not bound to the polymer backbone of the 
bioerodable polymer. In one well-characterized exam 
ple, a monolithic system based on the use of poly(DL 
lactide), a polymeric material that undergoes bulk deg 
radation, is disclosed. The physically entrapped thera 
peutic agent included in the polymer is released as the 
enzyme is activated by moisture. The moisture 
activated enzyme then degrades the polymeric slab, 
thus releasing the physically entrapped therapeutic 
agent. Release of the therapeutic agent is thus con 
trolled by a combination of diffusion and erosion. 
An objective of the present invention is to develop a 
slab of therapeutic agent-containing polymer which 
will release therapeutic agent at a relatively constant 
rate, the rate being affected by the enzymatic cleavage 
of the polymer by a preferred enzyme. The enzyme thus 
acts to internally control the physical release at a con 
stant rate of unbound homogeneously-dispersed thera 
peutic agent from the polymeric structure in which it is 
contained. 
As will be appreciated, the present invention is not 
taught or suggested by the art in general or the above 
described references. Particularly, the references do not 
address the specific inclusion of a moisture-activated 
enzyme in a polymeric device itself to enhance the rate 
of therapeutic drug delivery, such as the device de 
scribed by Kopachek, Schmidt and Williams. While 
Langer et al. describes an enzyme and polymer-bound 
drug delivery system, the art is void of any suggestion 
or teaching of a polymeric device with a non-polymer 
bound therapeutic agent and moisture-activated en 
zyme. The present system thus is not limited to thera 
peutic agents with structural characteristics suitable for 
binding to a polymeric substrate, and further features a 
therapeutic agent release rate independent of the rate at 
which drug-polymer bonds are enzymatically cleaved. 
This limitation as described in regard to the device of 
Langer et al. has been overcome by Applicants' with a 
system which physically entraps the therapeutic agent, 
without polymer bonding, the polymeric structure of 
the device. 
SUMMARY OF THE INVENTION 
The present invention has amazingly been able to 
overcome the limitations existing in the polymeric de 
vices of the past through the unique inclusion of both a 
non-polymer bound therapeutic agent and a moisture 
activated enzyme homogeneously dispersed within the 
polymeric structure itself. The constant and enhanced 
rate of drug release characteristic of the claimed device 
has been accomplished through the physical entrap 
ment of the drug within the matrices of the polymeric 
structure, rather than drug-polymeric bounding. Fur 
ther, its unique moisture-activated enzyme system 












surface. The device's constant rate of drug release is 
attributable to its unique coordinated action of included 
ingredients, whereby moisture-activated, enzymatic 
degradation of the slab facilitates the release of the 
unbound physically entrapped drug. A therapeutic 
agent is homogeneously dispersed in the polymeric 
substance by a variety of methods, for example by inclu 
sion during polymerization to form the polymeric Sub 
stance or mixture with a liquid polymeric substance and 
conversion of the liquid form to a solid form. 
An important aspect of the present invention is the 
presence of a homogeneously-dispersed enzyme in the 
polymer capable of degrading the polymeric substance 
in the presence of moisture or water. This degradation 
facilitates release of therapeutic agents physically en 
trapped in the polymeric structure. The therapeutic 
agent is not to be chemically bound to the backbone of 
the polymeric structure. Thus, release of the therapeutic 
agent is not dependent upon the action of the enzyme to 
cleave polymer-therapeutic agent bonds. Additionally, 
the rate of drug release is not limited by the rate at 
which enzyme diffuses through the substrate, as the 
enzyme is homogeneously dispersed throughout the 
polymeric structure. One or more such enzymes may be 
included homogeneously dispersed within the poly 
meric substance itself as was the therapeutic agent 
above. An enzyme may also be situated or dispersed in 
proximity to a surface of the polymeric substance so 
that, when moisture is present, for example that usually 
on the skin, the enzyme is active and degrades the poly 
meric substance from its surface. 
The present invention further includes a transdermal 
therapeutic agent-delivery device comprising a poly 
meric substance with an incorporated therapeutic 
agent. Also present in the transdermal therapeutic 
agent-delivery device is at least one enzyme homoge 
neously dispersed within the polymer which degrades 
the polymeric substance in the presence of moisture. 
The transdermal therapeutic agent-delivery device ad 
ditionally comprises means for holding the device in 
contact with a biological surface, such as to the skin of 
humans or animals. Such means, by way of example, 
include bandaging tapes, elastic bands and adhesive 
surfaces. 
Enzyme-degradable polymeric substances usable in 
the practice of the present invention are frequently in 
the general categories commonly known as polyesters, 
polyamides, polypeptides or polysaccharides. Certain 
typical enzyme-degradable polymeric substances have 
long been used as biodegradable materials for sutures, 
for example. These typical enzyme-degradable materi 
als include polyesters of alkylhydroxylic acids includ 
ing, for example, the polyesters of monomeric units 
such as lactic acid, glycolic acid, hydroxypropionic 
acid, hydroxybutyric acid and combinations thereof. 
Lactic acid and glycolic acid are most commonly used 
for this purpose. Other enzyme-degradable polymers 
well-known in the field include polymeric substances 
such as cellulose, dextran, elastin, fibrin, gelatin, poly 
ethylene, pectin or polygalacturonic acid. 
Enzymes usable in the practice of the present inven 
tion are of a wide variety but most frequently are pro 
teases or hydrolases with ester-hydrolyzing capabilities. 
Particularly preferred enzymes include proteinase K, 
bromelain, pronase E, cellulase, dextranase, elastase, 
plasmin, streptokinase, trypsin, chymotrypsin, papain, 
chymopapain, collagenase, trypsin, subtilisin, clos 
tridopeptidase A, ficin, carboxypeptidase A, pectinase, 
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pectinesterase, an oxidoreductase or an oxidase. The 
most preferred enzymes include proteinase K, brome 
lain and pronase E. The enzymes of the present inven 
tion are homogeneously incorporated in the polymeric 
substance. 
Therapeutic agents useful in the practice of the pres 
ent invention are of a wide variety but most frequently 
are antiparasitic, motion-sickness preparations, hor 
monal agents, diuretics and the like. These agents are 
physically entrapped in a homogeneous dispersion 
within the polymeric substance and are included in 
therapeutically effective amounts. For purposes of this 
application, a therapeutically effective amount is a 
quantity of therapeutic agent which elicits a physiologi 
cally beneficial effect. A pharmacologically acceptable 
material as used in this application comprises a material 
which is non-toxic to living organisms. 
The most preferred embodiment of the present inven 
tion comprises a poly(DL-lactide) polymeric slab, pro 
teinase Kenzyme at about 0.5% by weight of the slab 
and the therapeutic agent chlorpheniramine maleate. 
The present invention also features a method of trans 
dermal drug delivery, in which the described polymeric 
structure is employed together with a means for attach 
ing the structure to a biological surface, such as a pa 
tient's skin. 
The polymeric substance of the transdermal thera 
peutic agent-delivery device is characterized as having 
a surface for skin contact. The enzyme may be dispersed 
on said surface or homogeneously dispersed in the poly 
meric substance itself. The transdermal therapeutic 
agent-delivery device of the present invention is also 
useful for topical treatment of cutaneous lesions. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 1.23 dL/g which was not ex 
posed to any buffer. 
FIG. 2 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 1.23 d/g was exposed to 0.1M 
Tris buffer (pH = 8.0) for 4 days (from vial #1). 
FIG. 3 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 1.23 dL/g which was exposed to 
0.1M Tris buffer (pH = 8.0), containing 1 mg. of protein 
ase K, for 4 days (from vial #2). 
FIG. 4 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 1.23 dL/g which was exposed to 
0.1M Tris buffer (pH = 8.0), containing 2 mg. of protein 
ase K, for 4 days (from vial #3). 
FIG. 5 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 1.23 dI/g which was exposed to 
0.1M Tris buffer (pH = 8.0), containing 4 mg. of protein 
ase K, for 4 days (from vial #4). 
FIG. 6 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 1.23 dI/g which was exposed to 
0.1M Tris buffer (pH = 7.8), containing 10 mg. of pro 
nase E, for 4 days (from vial #6). 
FIG. 7 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 1.23 dL/g which was exposed to 
0.1M Tris buffer (pH = 7.8), containing 20 mg. of pro 
nase E, for 4 days (from vial #7). 
FIG. 8 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 1.23 dL/g which was exposed to 
0.1M Tris buffer (pH = 7.8), containing 100 mg. of pro 
nase E, for 4 days (from vial #9). 
FIG. 9 shows 10% chlorpheniramine maleate and 












0.1M Phosphate buffer (pH = 7.4), containing 100 mg. 
of bromelain, for 4 days (from vial #11). 
FIG. 10 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 1.23 dL/g which was exposed to 
0.1M Phosphate buffer (pH = 7.4), containing 200 mg. 
of bromelain, for 4 days (from vial #12). 
FIG. 11 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 1.23 dL/g which was exposed to 
0.1M Phosphate buffer (pH = 7.4), containing 500 mg. 
of bromelain, for 4 days (from vial #13). 
FIG. 12 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 0.71 dL/g which was exposed to 
0.1M Tris buffer (pH = 8.0) for 24 hours. 
FIG. 13 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 0.71 dL/g which was exposed to 
0.1M Tris buffer (pH = 8.0) for 24 hours-note: same 
slab as in FIG. 12-a different area of the slab. 
FIG. 14 shows 10% chlorpheniramine maleate and 
90% poly(DL-lactide) 0.71 dL/g which was not ex 
posed to any buffer. 
FIG. 15 shows 10% chlorpheniramine maleate, 1% 
proteinase K, and 90% poly(DL-lactide) 0.71 dL/g 
which was exposed to 0.01M Tris buffer (pH = 8.0) for 
24 hours. 
FIG. 16 shows 10% chlorpheniramine maleate, 1% 
proteinase K, and 90% poly(DL-lactide) 0.71 dL/g 
which was exposed to 0.01M Tris buffer (pH = 8.0) for 
24 hours-note: same slab as in FIG. 15. 
FIG. 17 shows the rate of drug release of chloro 
pheniramine maleate as a function of proteinase Ken 
zyme concentration in the polymeric slab. 
FIG. 18 shows the rate of drug release and polymeric 
slab weight loss in slabs containing 0.5% proteinase K 
enzyme over a seven day test period. 
FIG. 19 shows the effect of different enzymes on 
drug release from a polymer slab. The enzymes com 
pared include proteinase K, trypsin and chymotrypsin. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENT 
In the specification and the accompanying claims, the 
term "therapeutic agent' broadly includes physiologi 
cally or pharmacologically active substances producing 
a general or localized systemic effect in mammals in 
cluding humans and primates; avians; valuable domestic 
household, sport or farm animals; or for administering 
to laboratory animals such as mice, rats, guinea pigs; 
and the like. That is, the novel therapeutic agent deliv 
ery device can be used for administering therapeutic 
agents that are physiologically or pharmacologically 
active at a point in near relation to the therapeutic agent 
delivery device, or, for administering a systemically 
active substance which will produce a physiological or 
pharmacological response at a site remote from the 
point of application of the therapeutic agent delivery 
device. 
The therapeutic agents that can be administered by 
the claimed device include, without limitation, for ex 
ample, therapeutic agents acting on the central nervous 
system such as, hypnotics and sedatives such as pento 
barbital sodium, phenobarbital, secobarbital, thiopental, 
etc; heterocyclic hypnotics such as dioxopiperidines, 
and glutarimides; hypnotics and sedatives such as am 
ides and ureas exemplified by diethylisovaleramide an 
alpha-bromoisovaleryl urea and the like; hypnotics and 
sedative alcohols such as carbomal, naphthoxyethanol, 
methylparaphenol and the like; and hypnotic and seda 
tive urethans, disulfanes and the like; psychic energizers 
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such as isocarboxazid, nialamide, phenelzine, imipra 
mine, tranylcypromine, pargylene and the like; tranquil 
izers such as chloropromazine, promazine, fluphenazine 
reserpine, deserpidine, meprobamate, benzodiazepines 
such as chlordiazepoxide, and the like; anticonvulsants 
such as primidone, diphenylhydantoin, ethotoin, 
pheneturide, ethosuximide and the like; muscle relax 
ants and anti-parkinson agents such as mephenesin, me 
thocarbomal, trihexylphenidyl, biperiden, levo-dopa, 
also known as L-dopa and L-alpha-3-4 dihydroxyphe 
nylalanine, and the like; analgesics such as morphine, 
codeine, meperidine, nalorphine and the like; antipyret 
ics and anti-inflammatory agents such as aspirin, salicyl 
amide, sodium salicylamide and the like; local anesthet 
ics such as procaine, lidocaine, naepaine, piperocaine, 
tetracaine, dibucaine and the like; antispasmodics and 
antiulcer agents such as atropine, scopolamine, meth 
scopolamine, oxyphenonium, papaverine, prostaglan 
dins such as PGE1, PGE2, PGF, PGF2, PGA and the 
like; anti-microbials such as penicillin, tetracycline, 
oxytetracycline, chlorotetracycline, chloramphenicol, 
sulfonamides and the like; antimalarials such as 4 
aminoquinolines, 8-aminoquinolines and pyrimeth 
amine; hormonal agents such as prednisolone, hydro 
cortisone, cortisol and triancinolone; androgenic ste 
roids, for example, methyltestosterone, fluoximesterone 
and the like; estrogenic steroids, for example, 7B 
estradiol and ethinyl estradiol; progestational steroids, 
for example 17a-hydroxyprogesterone acetate, 19-nor 
progesterone, norethindrone and the like; sympathemi 
metic therapeutic agents such as amphetamine, 
ephinephrine, epinephrine and the like; cardiovascular 
therapeutic agents, for example, procainamide, amyl 
nitrite, nitroglycerin, dipyridanole, sodium nitrate, iso 
sorbide dinitrate and the like; diuretics, for example, 
chlorothiazide, flumethiazide and the like; antiparasitic 
agents such as bephenium hydroxynaphthoate and di 
chlorophen, dapsone and the like; anti-neoplastic agents 
such as mechlorethanine, adriamycin, methotrexate, 
uracil mustard, 5-fluorouracil, 6-thioguanine, procarba 
zine and the like; hypoglycemic therapeutic agents such 
as insulins, protamine zinc insulin suspension, globin 
zinc insulin, isophane insulin suspension, and other art 
known extended insulin suspensions, sulfonylureas such 
as tolbutamide, acetohexamide, tolazamide, and chlor 
propamide, the biguanides and the like; nutritional 
agents such as vitamins, essential amino acids, essential 
fats and the like; and other physiologically or pharma 
cologically active agents. 
Also, the therapeutic agents can be present as the 
pharmacologically acceptable derivatives, such as 
ethers, esters, amides, acetals, etc. that lend themselves 
to passage into the circulatory system. These deriva 
tives can be prepared by art known techniques and then 
used in the practice of the invention. Of course, the 
therapeutic agent derivative should be such as to con 
vert to the active therapeutic agent within the body 
through the action of body enzyme-assisted transforma 
tion, pH, specific organ activities, and the like. When a 
proteolytic enzyme is comprised by the device or com 
position of the present invention, polypeptide agents 
which are degraded by the enzyme should be avoided. 
The amount of therapeutic agent present in the poly 
meric substance is a therapeutically effective amount, 
which is generally non-limited and is an amount equal 
to or larger than the amount of a therapeutic agent that, 
on its release from the polymeric substance, is effective 












logical effects. For example, the amount of therapeutic 
agent present in the polymeric substance of a therapeu 
tic agent-delivery device should be suitable for main 
taining a supply of therapeutic agent when the device is 
used for a period of time to achieve local or systemic 
effects. For various therapeutic agents, such as 11 
desmethoxyreserpine about 5 to 40 mg in the polymeric 
substance, may be suitable. For acetophenazine a suit 
able amount in the polymeric substance should be from 
100 to 200 mg. 
It will be appreciated by those versed in the art that 
the unique therapeutic agent delivery device of this 
invention can provide for the programmed delivery of 
therapeutic agent at a rate of delivery characterized by 
a zero order time dependence for prolonged periods of 
time; and, that the device therefore lends itself to admin 
istering an effective amount of therapeutic agent needed 
for a therapeutic effect while essentially avoiding the 
presence of excessive amount of therapeutic agent at the 
needed biological site. For example, the amount of ther 
apeutic agent in the polymeric substance can be 10 to 30 
mg of thiopropazate for releasing 5 to 10 mg over a 
given time; 100 to 200 mg in the polymeric substance of 
phenyltoloxamine for a release of 50 mg; 100 to 200 mg 
of papaverine in the polymeric substance for a release of 
30 to 75 mg over a determined time; 500 to 600 mg of 
mephenoxalone for a release of 375 to 425 mg. 
The present invention involves a device comprising a 
biodegradable polymeric slab preferably containing a 
therapeutic agent, a plasticizer and an enzyme. Such a 
device may be used for the slow release or transdermal 
delivery of the therapeutic agent. Bioerodible polymers 
such as DL-polylactic acid and polyglycolic acid have 
been used for many years in absorbable sutures. The 
most preferred embodiment of the present invention 
comprises a polymeric slab of poly (DL-lactide), the 
enzyme proteinase K, and the therapeutic agent chloro 
pheniramine maleate. Most preferably, the concentra 
tion of proteinase K is about 0.5% by weight of the 
polymeric slab. 
During the past fifteen years, systemic delivery of 
therapeutic agents by means such as therapeutic agents 
dispersed in biodegradable microspheres or pellets for 
implantation, has been reported. The polymers are hy 
drolyzed slowly over a period of weeks to several 
months to release the active component. The polymer 
degrades extremely slowly in water and without the 
presence of the enzyme in the polymer, topical thera 
peutic agent release from the polymeric slab would be 
overly slow. The inclusion of a plasticizer in the poly 
meric substance of the present device adds elasticity to 
the membrane so that it may follow the contours of the 
skin surface to which it is applied. 
Drug release from the polymeric substance of the 
present invention is triggered by the enzymatic hydro 
lysis of the polymer that occurs in the presence of water 
or in the presence of the moisture in the surface layers 
of the skin. As the polymer (e.g., DL-polylactic acid) 
degrades to a monomer (lactic acid), the physically 
entrapped therapeutic agent is released from the slab 
and is available for percutaneous absorption through 
the skin. Most experience to date has been with a model 
monolithic system based on the use of poly (DL-lactide) 
which undergoes bulk degradation. This means that 
therapeutic agent release is controlled by a combination 
of diffusion and erosion. The enzymatic cleavage of the 
ester backbone of the polymer may be conducted with 
appropriate degradative enzymes. Studies have thus far 
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found the enzyme proteinase K to have the most pro 
nounced physical effect on the degradation of poly 
(DL-lactide) compared to other enzymes studied. 
Since the polymers may be applied internally or to 
the surface of the skin, pharmacologically acceptable 
biocompatable polymers are preferred for the present 
invention. These include polymers that might not nor 
mally be injected or implanted into the body since they 
would not be broken down to readily metabolizable 
monomers. Usable polymers may include, for example, 
cellulose, dextran, elastin, fibrin, gelatin, polyethylene, 
polyesters and polyamides. All of these polymers may 
undergo enzymatic degradation to monomers that are 
harmless or inactive to the skin surface or other biologi 
cal structures. 
The composition of the present invention may also be 
used for the internal emission of therapeutic agents. 
This internal emission of therapeutic agents may, for 
example, be in the digestive tract, the muscle or in prox 
imity to a joint. Administration of the enzyme and ther 
apeutic agent-containing polymeric substance of the 
present invention would respectively be by ingestion, 
intramuscular insertion or intraarticular insertion. In 
gestion would lead to release of the therapeutic sub 
stance in the intestinal system when incorporated en 
zyme degrades the polymeric substance. 
With intramuscular or intraarticular insertion, for 
example by injection of emulsification-produced parti 
cles having a size of less than 50 microns, the therapeu 
tic agent would be released as the polymeric substance 
was degraded to metabolizable or excretable mono 
meric units. The composition of the present invention 
could also be internally utilized as larger pieces which 
were enzymically dissolved as therapeutic agent was 
exhausted. Such internal uses could be therapeutically 
or prophylactically used with humans or with animals. 
When cattle, for example, are treated with an implanted 
composition, the composition may be prepared to be 
totally degraded by the time the cattle are slaughtered 
for consumption. 
Present marketed dosage forms utilize two mecha 
nisms for controlling therapeutic agent release from a 
transdermal therapeutic agent-delivery system. The 
first and most popular method is the membrane diffu 
sion controlled system. The other two systems that are 
on the market involve therapeutic agent release from a 
polymeric matrix. In these systems, very small quanti 
ties of therapeutic agent are released from the matrix. 
One major problem with matrix systems is that small 
quantities of therapeutic agent are released and in many 
cases the system essentially shuts off and does not re 
lease adequate amounts of further medication. The pres 
ent biodegradable system circumvents these problems. 
Preliminary studies have shown that release rates are 
constant and very dependent on the level of enzyme in 
the slab or film of the present invention. For example, 
data presented at FIG. 17 demonstrates the increase in 
release of the therapeutic agent chlorpheniramine male 
ate as a function of increasing concentrations of the 
enzyme proteinase K in the polymeric slab. 
The present transdermal systems require the presence 
of moisture on an occluded surface to trigger therapeu 
tic agent release from the device. More specifically, 
accumulation of moisture on the biological surface acti 
vates the enzyme to degrade the polymeric slab, 
thereby releasing the therapeutic agent physically en 












Where the enzyme is not compatible with the organic 
solvent that would be used to cast these slabs, the en 
zyme could be applied to the outer surface of the slab in 
sufficient quantities to trigger polymeric degradation 
while the device is present on the skin. Since the matrix 
system generally has limitations for many therapeutic 
agents, there are presently few alternatives to men 
brane diffusion control systems. 
The device of the present invention should also have 
applications in the animal health area for the topical 
delivery of therapeutic agents to the skin surface for a 
wide variety of animals. There could also be some po 
tential applications in flea and tick collars where an 
insecticide would be released by the triggering action of 
the water and enzyme causing erosion of the polymer, 
as described above. 
Table 1 shows many compatible combinations of 
polymeric materials and degradative enzymes useful or 
potentially useful in the practice of the present inven 
tion. 
TABLE 1. 
Polymer Enzyme(s) Monomers(s) 
1. Cellulose Cellulase Hexose Sugars 
2. Dextran Dextranase Glucose(primarily) 
3. Elastin Elastase Peptides(? 
4. Fibrin Plasmin Short Polypeptides 
Streptokinase Short Polypeptides 
Trypsin, Short Polypeptides 
Chymotrypsin Short Polypeptides 
Papain, Short Polypeptides 
Chymopapain Short Polypeptides 





6. Polyamides Chymotrypsin 
7. Poly. Trypsin Short Polypeptides 
(amino acids) Chymotrypsin 
(e.g. poly- Elastase 
lysine, poly- Subtilisin 
glutanic acid) 
8. Polyethylene Oxidoreductase 
Oxidase 




10. Poly(hydroxy- Carboxypeptidase A Short Acid Chains 
alkyl acids) chymotrypsin and hydroxy 
e.g-poly- Ficin Acids 
lactic acid, Proteinase K 
polyglycolic Bronnelain 
acid Pronase E 
A preferred enzyme usable in the practice of the 
present invention is the fairly nonspecific protease, pro 
teinase K. This enzyme is active even under extreme 
conditions which include: (a) high temperature 
reported to be 12 times more active at 65° C. than at 25 
C.; (b) extreme pH-active at pH 4 through pH 12.5. 
Preliminary work with this and a number of other en 
zymes has indicated that proteinase K has a pronounced 
physical effect of degradation on poly(DL-lactide). 
A particular model system presently developed in 
volves a slab comprising poly(DL-lactide), the enzyme 
proteinase K, and chlorpheniramine maleate as the 
model therapeutic agent. These devices were fabricated 
by dissolving therapeutic agent and poly(DL-lactide) in 
methylene chloride, suitably dispersing proteinase K in 
the solution (when enzyme was added), casting the 
mixture on a mold, such as an aluminum surface, and 
then evaporating the solvent at room temperature. The 
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dissolution of the prepared slab is then carried out using 
a modified version of the USP Apparatus 2 Method of 
Dissolution. Samples of the dissolution media were 
taken periodically and assayed for chlorpheniramine 
maleate using UV spectrophotometry. This method 
allowed the release of the therapeutic agent in the pres 
ence and absence of the enzyme to be followed. In 
addition, the method of scanning electron microscopy 
(SEM) was used to physically observe the effect of the 
enzyme in the polymer slab. 
Assay results have shown that an increase in the en 
zyme concentration in the slab caused an increase in 
therapeutic agent release from the system. At one per 
cent level of enzyme (as opposed to no enzyme) in the 
slab, a 6-fold increase in therapeutic agent release was 
found after a 24-hour dissolution study (FIG. 17). In 
addition, SEM results showed that slabs with enzyme 
exhibited major surface erosion after being subjected to 
the dissolution media for 24 hours. A slab containing 
2% proteinase K showed a 12 fold increase in drug 
release after 24 hr. 
These examples are presented to describe preferred 
embodiments and utilties of the present invention and 
are not meant to limit the present invention unless oth 
erwise stated in the claims appended hereto. 
EXAMPLE 
Effect of Enzymes on Poly(DL-Lactide) Slabs 
Containing Model Therapeutic Agents 
Materials and Methods for Slab Prepara 
tion-poly(DL-lactide) of inherent viscosity 1.23 dL/g 
was used in this test. Slabs were prepared by weighing 
a quantity of chlorpheniramine maleate (the model ther 
apeutic agent) that would give 50 mg. of therapeutic 
agent per slab (10% w/w), dissolving the therapeutic 
agent in a small amount of methylene chloride in a 
beaker, adding a quantity of the poly(DL-lactide) 1.23 
that would give 450 mg. of polymer per slab (90% 
w/w), and finally bringing the solution to a final volume 
that would allow 5 ml. of the therapeutic agent 
/polymer solution to contain 50 mg. of therapeutic 
agent and 450 mg. of polymer. After mixing well, 5 ml. 
quantities of the solution were cast into 4.4 cm. alumi 
num dishes. The slab-containing dishes were then 
placed on a laboratory benchtop, covered with alumi 
num foil, and left for a 24 hour period to allow the 
methylene chloride to evaporate. At the end of 24 
hours, the slabs were placed in a desiccator with cal 
cium sulfate until ready for the study. 
Enzyme solution content-Tris 0.1M buffer solutions 
with pH's of 7.8 and 8.0 and a 0.1M phosphate, 50 mM 
EDTA, and 5 mM cysteine buffer with a pH of 7.4 were 
prepared. pH's were adjusted with concentrated HCl. 
Test set-up and Results-2 small circles (approx. 2 
cm. in diameter each) were cut from each slab (see FIG. 
1). Each circular piece of slab was placed in a 20 ml. 
glass scintilation vial. Various solutions were then 
placed in each vial. The contents of the solutions placed 
in the vials were as follows: 
Wial if Contents 
l 5 ml. of pH 8.0 Tris Buffer (see FIG. 2) 
2 5 ml. of pH 8.0 Tris Buffer + 1 mg. of proteinase 
K (see FIG. 3) 
3. 5 ml. of pH 8.0 Tris Buffer + 2 mg. of proteinase 
K (see FIG. 4) 













Vial if Contents 
-man-mmunay 
K (see FIG. 5 
5 5 mi. of pH 7.8 Tris Buffer 
6 5 mi. of pH 7.8 Tris Buffer + 10 mg. of pronase E 
(see FIG. 6) 
7 5 mi. of pH 7.8 Tris Buffer + 20 mg. of pronase E 
(see FIG. 7) 
8 5 ml. of pH 7.8 Tris Buffer + 30 mg. of pronase E 
9 5 mi. of pH 7.8 Tris Buffer + 100 mg. of pronase 
E (see FIG. 8) 
10 5 ml. of pH 7.4 Phosphate Buffer 
11 5 ml. of pH 7.4 Phosphate Buffer + 100 mg. of 
bromelain (see FIG.9) 
5 ml. of pH 7.4 Phosphate Buffer -- 200 mg. of 
bromelain (see FIG. 10) 
5 ml. of pH 7.4 Phosphate Buffer + 500 mg. of 
bromelain (see FIG. 11) 
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Once all vials were prepared, they were incubated in 
a shaking water bath set at 32 C. All solutions were 
replaced very 24 hours to better ensure that an active 
enzyme was kept in contact with those samples contain 
ing enzyme solutions. The study was run for 4 days. At 
the end of 4 days, the condition of the slab samples was 
noted. 
In all cases, the samples in contact with buffer solu 
tion showed no evidence of surface erosion. The sam 
ples in contact with the enzyme solutions had a dull 
surface evidencing erosion had occurred. Some of the 
samples were observed under a scanning electron mi 
croscope in order to observe the surface of the samples 
under high magnification. The scanning electron micro 
graphs are shown in FIGS. 1-16. 
EXAMPLE 2 
Effect of Enzymes on Poly(DL-Lactide) Slabs 
Containing Model Therapeutic Agents 
The same method of preparation of slabs was per 
formed as described in Example 1 except that before 
casting the slab solution into aluminum dishes, a fine 
powder of the enzyme proteinase K was added to the 
solution so that a concentration of 1% w./w was ob 
tained in the slab. As a result of this, the chlorphenira 
mine maleate concentration remained 10% w/w but the 
polymer concentration became 89% w/w. The suspen 
sion of the enzyme in the slab solution was then mixed 
by stirring. The slabs were then cast and evaporated as 
described in Example 1. 
Poly(DL-lactide) with an inherent viscosity of 0.71 
dL/g was used in this study. 
Slabs were also prepared with 10% w/w chlorphen 
iramine maleate and 90% w/w poly(DL-lactide) 0.71 
using the same procedure as noted for Example 1. 
Dissolution Study Set-up and Results-The USP 
Apparatus 2 Method of Dissolution was used to check 
the release rate of both sets of slabs (with and without 
enzyme). The dissolution test methods were as follows: 
Temperature-32'-0.5' C. 
Speed of Paddles-30 rpm 
Dissolution Media-0.01 M Tris Buffer (pH 8.0) 
Samples of the dissolution media were taken periodi 
cally and assayed for chlorpheniramine maleate using 
UV spectrophotometry. This allowed the release of the 
therapeutic agent in the presence and absence of the 
enzyme to be followed. Results of the UV assay, 
showed at the one per cent level of enzyme (as opposed 
to no enzyme) in the slab, a 5- to 6-fold increase in 
therapeutic agent release was found after a 24-hour 
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dissolution study. In addition, scanning electron micros 
copy results showed that slabs with enzyme exhibited 
major surface erosion after being subjected to the disso 
lution media for 24 hours. Pictures of the scanning elec 
tron micrographs are attached at the end of this report. 
Please note that the enzyme used in this study had a 
reported activity of 17 U/mg. of protein (using casein as 
the substrate). 
EXAMPLE 3 
Effects of Plasticizers on Slab Formation 
Plasticizers are preferred inclusions in the composi 
tion of the present invention. Numerous plasticizers are 
usable and known to those skilled in the art. 
Particular plasticizers were mixed in slabs with po 
ly(DL-lactide) 0.71 to determine which were most 
promising for formulation purposes. 
The specific plasticizers used and their concentra 
tions in the slabs were as follows: 
Plasticize % w/w in the Sab 
1. Triacetin 0, 15, 20, & 30 
2. Triethyl Citrate 0, 5, 20, & 30 
3. Dibutyl Phthalate 0, 5, 20, & 30 
4. Diethyl Phthalate 10, 15, 20, & 30 
5. Dioctyl Phthalate 10, 15, 20, & 30 
6. PVP K5 10, 15, 20 
7. PWP K30 10, 15, 20 
8. PVP K90 10, 15, 20 
The slabs were prepared by weighing the amount of 
plasticizer needed to acquire the desired 9% w/w con 
centration (based on a final total slab weight of 500 
mg.), then dissolving the plasticizer in 5 ml. of methy 
lene chloride, adding the needed amount of poly(DL 
lactide) 0.71 to reach a slab weight of 500 mg., and then 
casting the solution in a 4.4 cm. aluminum dish. All the 
dishes were covered with aluminum foil, evaporated 24 
hours on the benchtop, and then put in a desiccator with 
anhydrous calcium sulfate until ready for observation. 
1. Triacetin, triethyl citrate, dibutyl phthalate, and 
diethyl phthalate gave relatively clear, plastic slabs up 
to a concentration of 20% w/w. A concentration of 
30% in each case produced a sticky slab at room tem 
perature and humidity. 
2. Dioctyl phthalate did not produce as desirable a 









plasticizer produced a slightly sticky slab at a 20% w/w 
concentration whereas the others already mentioned 
did not. 
3. Of the three PVP's (polyvinylpyrrolidones), PVP 
K90 produced the most homogeneous slabs (in appear 
ance) even up to a concentration of 20% w/w. 
EXAMPLE 4 
Enzyme Dispersed on the Surface of a Polymeric 
Substance 
A slab of 10% chlorpheniramine maleate and 90% 
poly(DL-lactide) 0.71 dL/g was prepared following the 
procedure described in Example 1. Once the slab was 
cast, the methylene chloride was allowed to evaporate 
until the slab just formed. Then, a suspension was made 
by adding 10 mg. of finely powdered proteinase K to a 
2.5% solution of Klucel LF in methylene chloride. 2 ml 
of this suspension were pipetted onto the surface of the 
slab and spread evenly over the slab. The slab-contain 
ing dish was then covered with aluminum foil, left sit 
ting on the benchtop for 24 hours, and then placed in a 
desiccator containing calcium sulfate until ready for 
observation. 
Observation of slab-The slab had a smooth appear 
ance and the enzyme was spread evenly over the sur 
face of the slab. 
EXAMPLE 5 
Effect of Enzymes on Poly(DL-Lactide) Slabs 
Prepared from Lower Viscosity Poly(DL-Lactide) 
The procedures as described in Examples 1 and 2 
were performed but with polylactide of a lower viscos 
ity (0.71 dI/g). FIG. 14 shows a scanning electron 
micrograph of the resultant slab. FIGS. 12 and 13 show 
a SEM of this slab after a 24 hr exposure to 0.1M Tris 
buffer (pH = 8.0). FIGS. 15 and 16 show SEM of low 
viscosity poly(DL-lactide) slabs comprising 1% prote 
inase K after a 24 hr exposure to 0.01M Tris buffer 
(pH = 8.0). 
EXAMPLE 6 
Materials and Suppliers of Materials Used to Prepare 
and Test Films of Poly(DL-Lactide) 
Table 2 indicates the source of various reagents used 
in development of the present invention. 
TABLE 2 
MATERIAL SUPPLIER DESCRIPTION OF MATERIAL 
1. Proteinase K Sigma Chemical Co. 
2. Pronase E Signa Chemical Co. 
3. Bronnellain Sigma Chemical Co. 
4. Chlorpheniramine Sigma Chemical Co. 
Maeate 
5. Methylene Fisher Scientific Co. 
Chloride 
6. Poly(DL-lactide) Southern Research 
Institute 
7. Trizrna Base Sigma Chemical Co. 
Cat, #PO390-Type XI: Fungal; Lyophilized powder from 
Tritirachium album; Activity = 10-20 units per mg. 
protein (Biuret); Protein > 90%; Substantially free of 
DNase and RNase 
Cat. #P5147-type XIV; Bacterial; AN unusually non 
specific protease from Streptomyces griseus; 
essentially starch free; contains approx. 15% calcium 
acetate; Activity = approx. 4 units per ng, solid 
Cat, if B2252-Fron Pineapple stem; Contains approx. 50% 
protein (Biuret); Activity = 2000-4000 units per gram 
protein; Unit definition-one unit will hydrolyze 1.0 mg 
of amino nitrogen from gelatin in 20 minutes at pH at 
45 C. 
Cat. C3025 
Ct. #D143-HPLC Grade; Fisher certified ACS 
Materials tested to date have 
inherent viscosities of 1.23 divg and 0.71 di?g 
(determined in chloroform) 
Cat. #T1503-White crystalline powder; Mol Wt. 121.1; 




MATERIAL SUPPLIER DESCRIPTION OF MATERIAL 
(min.) (acid-base titration) 
8. Concentrated Fisher Scientific Co. Cat. # Al44-Fisher Reagent 
Hydrochloric ACS 
Acid 
9. Potassium MCB Manufacturing Cat. #PXl 570-Powder, Reagent 
Phosphate Chemists, Inc. ACS 
Dibasic 
10. Potassium Fisher Scientific Co. Cat. P285-Fisher Certified 
Phosphate ACS 
Monobasic 
ll. Dipotassium Sigma Chemical Co. Cat. #ED2P-Approx. 98% 
Salt EDTA Crystalline 
12, L-Cysteine HCL Sigma Chemical Co. Cat. #C1276-Anhydrous; 
Crystalline 
13. Distilled Water-Made in the laboratory when needed 
14. Triacetin Fluka Chemical Corp. Cat. #90240-purum quality 
15. Polyvinyl- Fluka Chemical Corp. Cat. #81440-purum quality 
pyrrollidone 
K15, 30, & 90 
16. Diethyl Fluka Chemical Corp. Cat. #80080-purum quality 
Phthalate 
17. Dibuty} Sigma Chemical Co. Cat. #D2270 
Phthalate 
18. Dioctyl Fluka Chemical Corp. Cat. #80032-purum quality 
Phthaiate 
19. Triethyl Aldrich Chemical Co. Cat. # 10, 9290-99% 
Citrate 
20. Kuce LF Hercules Inc. Sample 
-continued EXAMPLE 7 
Suggested Method for Preparing Slabs by Compression 30 
Method 
A. Micronized materials should be used. 
B. Poly(DL-lactide) should be blended with thera 
peutic agent and enzyme for 5 minutes using the method 
of geometric dilution to ensure a homogeneous blend of 
the constituents. 
C. The blended material should then be placed in a 
compression mold and the mold placed in a press that 
will allow the material to be heated prior to and during 
compression. 
D. The press, containing the mold and material, 
should be heated to a temperature of 65 C. 
E. The material should then be compressed at a pres 
sure of about 10,000 lbs. for approximately 10 minutes. 
F. At the end of 10 minutes, the compressed material 
should be cooled for 6 minutes, under compression 
pressure, using a combination of air and water (at room 
temperature) which is circulated around the compres 
sion plates. 
G. At the end of the cooling cycle, the pressure is 
released and the plates and slab are removed from the 
press. 
H. Note: The flexibility of the slabs produced by this 
method can be modified by the use of plasticizers. If 
plasticizers are used, they should be added during the 
blending stage and if solid, should be micronized as the 
other constituents are. The plasticizers recommended 
for use with the poly(DL-lactide) systems are triacetin, 
diethyl phthalate, triethylcitrate, and polyvinylpyrroli 
done (PVP K90). 
Suggested formulas for solvent casting or compres 
sion molding include: 
Formula fil: Chlorpheniramine Maleate 1% w/w to 
10% w/w 
Triacetin 5% w/w to 20% w/w 






Proteinase K 0.0% w/w to 20% w/w 
(recommended 2% to 5%) 
Poly(DL-lactide) qs to 100% 
Chlorpheniramine Maleate 1% w/w to 
10% w/w 
Triethyl Citrate 5% w/w to 20% w/w 
(recommended 10% to 15%) 
Proteinase K 0.01% w/w to 20% w/w 
(recommended 2% to 5%) 
Poly(DL-lactide) qs to 100% 
Chlorpheniramine Maleate 1% w/w to 
10% w/w 
Diethyl Phthalate 5% w/w to 20% w/w 
(recommended 10% to 15%) 
Proteinase K 0.01% w/w to 20% w/w 
(recommended 2% to 5%) 
Poly(DL-lactide) qs to 100% 
Chlorpheniramine Maleate 1% w/w to 
10% w/w 
Polyvinylpyrrolidone (PVP K90) 5% 
w/w to 20% w/w (recommended 10% to 
15%) 
Proteinase K 0.01% w/w to 20% w/w 
(recommended 2% to 5%) 
Poly(DL-lactide) qs to 100% 
Pronase E 0.0% w/w to 20% w/w 
Bromelain 0.01% w/w to 20% w/w 
Scopolamine Hydrobromide 0.01% w/w 
to 5% w/w 
NOTE: The formulas above can be used for slabs prepared either by the method of 






1. Solvent Casting Method-The therapeutic agent 
and plasticizer should be weighed out and dissolved in 
a small amount of methylene chloride. The poly(DL 
lactide) should then be added to the solution and the 
solution brought to a final volume which will allow 5 
mi. of solution to contain the required amount of each 
constituent. The enzyme (as a micronized powder) 
should then be added to this final solution (again in an 
amount which will allow 5 ml. of solution to contain the 
required amount of enzyme), stirred well, and then cast 
in 5 ml. quantities for each slab. The slab is allowed to 




2. Compression Molding Method-The therapeutic 
agent, plasticizer, and enzyme should be added to the 
poly(DL-lactide) by the method of geometric dilution. 
All materials must be micronized if solid. The mixture 
should then be blended for 5 minutes to ensure a homo- 5 
geneous material is made for compression. The blended 
material is then placed in compression mold and the 
mold placed in press that will allow the material to be 
heated prior to and during compression. The compres 
sion plates, containing the mold and material, is heated 
to a temperature of 65° C. The material should be com 
pressed at a pressure of 10,000 lbs. for 10 minutes. At the 
end of 10 minutes the compressed material is cooled for 
6 minutes, under compression pressure, using a combi 
nation of air and water (at room temperature) which is 
circulated around the compression plates. At the end of 
the cooling cycle, the pressure is released and the plates 
and slab are removed from the press. 
EXAMPLE 8 
Suggested Formulas for Films Prepared with Enzyme 
Applied to a Slab 
10 
20 
Formula i : 25 Botton Layer Chlorpheniramine Maleate 1% 
to 10% w/w 
Triacetin 5% to 20% w/w 
(recommended 10% to 15%) 
Poly(DL-lactide) qs to 100% 
w/w 
Proteinase K 0.01% to 20% 
w/w 
Klucel LF qs to 100% w/w 
Pronase E 0.01% to 20% w/w 
Bromelain 0.01% to 20% w/w 
Scopolamine Hydrobromide 0.01% to 0.5% 
w/w 
Diethyl Phthalate 5% to 20% w/w 
(recommended 10% to 15%) 
Polyvinylpyrrolidone (PVP K90) 5% to 
20% w/w (recommended 10% to 15%) 
Top Layer 30 
Other Enzymes: 
Other Drugs: 
Other Plasticizers: 35 
Method of Preparation 40 
The therapeutic agent and plasticizer should be 
weighed out and dissolved in a small amount of methy 
lene chloride. The poly(DL-lactide) should then be 
added to the solution and the solution brought to a final 
volume which will allow 5 ml. of solution to contain the 
required amount each constituent specified for the bot 
ton layer in the formula. After mixing the solution well, 
5 ml. quantities of the solution should be taken and cast 
to make each slab. Once cast, the methylene chloride 
should be allowed to evaporate and the slab to form. 
This will be the bottom portion of the final slab. A 
suspension is then made by adding the micronized en 
zyme to a solution of the Klucel LF in methylene chlo 
ride. The volume of methylene chloride used should be 
sufficient so that 2 ml. of the suspension will contain the 
required mounts of enzyme and Klucel LF specified in 
the formula for the top portion of the slab. Once made, 
2 ml. of the suspension are pipetted onto the surface of 
the slab and spread evenly over the slab. The slab is then 60 







Scanning Electron Microcopy was performed with a 
Joel JSM-35C scanning electron microscope (ACC 




In Vitro Release Studies 
In vitro experimental drug release studies were con 
ducted to determine the effect of an enzyme on polymer 
degradation involving preparing and studying drug 
release from slabs which contained drug, enzyme and 
polymers. Prior to Applicants' laboratory studies, the 
effects on drug release by including any enzyme in the 
drug-containing polymer slab was unknown. The pres 
ent study demonstrates the release-controlling potential 
of the inclusion of enzyme in such polymeric devices. 
For example, the presence of proteinase K (enzyme) 
in a poly (DL-lactide) slab was found to decrease the 
"lag" period of drug release as well as to enhance the 
rate of drug release linearly with the percent of protein 
ase K (enzyme) included in the slab. The polymeric 
slabs of the present example contained proteinase K 
enzyme ranging from 0% to 2% by weight of the slab. 
Polymer degradation upon exposure to a 0.01M tris 
buffer, (32° C., pH 8.0) was monitored over a 180 hour 
test period (FIG. 17). 
Materials 
The polymer used in this study was poly(DL-lac 
tide)(PLA) with inherent viscosities of 0.63, 0.71, 1.23, 
and 1.69 dL/g. (as determined in chloroform at a con 
centration of 5 mg/ml). The polymer was obtained from 
Southern Research Institute in Birmingham, Ala. All 
other materials and solvents used for film preparation 
and subsequent studies were purchased from various 
commercial sources and were used as received. These 
included: chlorpheniramine maleate, proteinase K, 
Trizma base, p-hydroxydiphenyl, rhodamine 6G dye 
(dye content of approximately 95%), lithium lactate 
(Sigma Chemical Co.); methylene chloride (HPLA 
grade), concentrated hydrochloric acid, calcium sulfate 
(8 mesh Drierite), supric sulfate, 85% phosphoric acid, 
sulfuric acid, sodium hydroxide, tetrahydrofuran 
(HPLC grade), (spectrophotometric grade, Aldrich 
Chemical Co.); pH 11, buffer (glycine/sodium hydrox 
ide/sodium chloride, Fluka Chemical Corp.). All sol 
vents and chemicals were A.C.S. reagent grade, unless 
otherwise indicated. 
Film Preparation 
Film samples containing PLA were prepared by a 
solvent casting method. This involved weighing a quan 
tity of chlorpheniramine maleate (if drug was to be in 
the films) that was 7.5% of the total solids weight and a 
quantity of PLA that would bring the total solids 
weight to 100%. These materials were dissolved in 
methylene chloride (20 ml/10 g of total solids) in a 
tightly stoppered, pyrex bottle. Proteinase K, if added, 
was added at this point as a fine powder which had been 
produced by sieving the enzyme, as received from the 
manufacturer, through a #140 sieve (3 inch, U.S. Stain 
less Steel Standard Sieve, Thomas Scientific.). All mate 
rials were mixed well with a stirring bar which had been 
placed in the stoppered bottle containing the film ingre 
dients. The resulting solution, or suspension if enzyme 
was present, was spread onto a piece of aluminum foil 
(Alufoil Products Co.) which was 0.003 inch thick. 
Each spread film was allowed to equilibrate at room 
temperature for approximately 12 hours to allow the 
methylene chloride present in the case mixture to evap 
orate. At the end of this time, each film, with its alumi 
num backing in place, was cut into 2 cm.X2 cm. Squares 
for degradation studies or 4 cm.X4 cm. squares for 
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release studies. The films, once cut, were placed in a 
vacuum desiccator over calcium sulfate. A vacuum of 
approximately 550 mm Hg was pulled on the desicca 
tor. All films prepared in this way were used in degra 
dation or release studies 6 to 7 days after preparation. 5 
Results 
As correlated to the referenced data in FIG. 17, the 
presence of as little as 2% proteinase K in the polymer 
slab increased the rate of drug release 9-fold over non 
enzyme containing slabs upon immersion in a 0.01M 
Tris buffer (32° C., pH 8.0) within 30 minutes. The rate 
of degradation of the polymeric slab was evidenced by 
a progressive loss in weight of the slab itself, and was 
correlatable to an increase in the rate of drug release 
observed in the test media. (FIG. 18). 
Data from these studies demonstrate a slower rate of 
polymeric breakdown in non-enzyme containing poly 
meric films. Additionally, comparative studies between 
proteinase K-containing poly (DL-lactide) slabs and 
chymotrypsin-, or trypsin-containing poly (DL-lactide) 
slabs in Example l l demonstrated slower drug release 
rates from slabs with 0.5% chymotrypsin or 0.5% tryp 
sin compared to drug release rates observed with 0.5% 
proteinase K-containing slabs (FIG. 19). 
EXAMPLE 11 






Comparative studies between proteinase K-contain 
ing poly(DL-lactide) slabs and chymotrypsin - or tryp 
sin - containing poly(DL-lactide) slabs were conducted. 
Slabs were prepared according to the methods outlined 
in Example 10. Slower drug release rates were demon 
strated from slabs with 0.5% chymotrypsin on 5% tryp 
sin compared to drug release rates observed with 0.5% 
proteinase K-containing slabs. 
The data obtained from this study is presented at 
FIG. 19. These results suggest the enzyme proteinase K 
possesses the highest poly(DL-lactide) degradation, 
thus facilitating the greatest rate of physically 
entrapped therapeutic agent therein. 
Changes may be made in the elements and assemblies 
described herein or in the steps or the sequence of steps 
of the method described herein without departing from 
the concept and scope of the invention as defined in the 
following claims. 
What is claimed is: 
1. A pharmacologically acceptable composition of 
matter comprising: 
a biodegradable polymeric slab; 
a moisture activated enzyme included within the 
polymeric slab in a therapeutic agent releasing 
concentration which enzymatically degrades said 
slab; 
a non-polymer bound therapeutic agent incorporated 
into said slab, 
wherein enzymatic degradation of the biodegradable 
polymeric slab releases the incorporated therapeutic 
agent at a rate which is a function of the concentration 60 
of the enzyme in the slab. 
2. A pharmacologically acceptable composition of 
matter for the time dependent liberation of a therapeutic 
agent in vivo, the composition consisting essentially of: 
a biologically degradable polymeric slab; 
a non-polymer bound, homogeneously dispersed 
therapeutic agent physically entrapped in said pol 








an enzyme included at a concentration within the 
polymeric slab which degrades said slab in the 
presence of moisture to facilitate the controlled 
release of entrapped therapeutic agent at a rate 
which is a function of the concentration of the 
enzyme in the slab. 
3. A deliver device for the transdermal administration 
of a therapeutic agent, said device comprising: 
a polymeric slab having a side for dermal contact; 
a non-polymer bound, homogeneously dispersed 
therapeutic agent physically entrapped in said pol 
ymeric slab; 
at least one moisture activated enzyme included 
within the slab at a concentration which provides 
for the controlled release of the therapeutic agent; 
and 
a means for holding the device in dermal contact, 
wherein the therapeutic agent is released at a rate which 
is a function of the concentration of the enzyme within 
the slab. 
4. The composition of claim 1 or 2 or delivery device 
of claim 3 wherein the polymeric slab comprises a poly 
mer selected from the group consisting of: 
polyesters, polyamides, polypeptides, polysaccha 
rides, cellulose, dextran, elastin, fibrin, gelatin, 
polyethylene, pectin, and polygalacturonic acid. 
5. The composition of claim 1 or 2 or delivery device 
of claim 3 wherein the polymeric slab comprises a bio 
degradable polyester. 
6. The composition of claim 1 or 2 delivery device of 
claim 3 wherein the polymeric slab comprises a polyes 
ter of biologically metabolizable monomeric units se 
lected from the group consisting of lactic acid, glycolic 
acid, hydroxypropionic acid, and hydroxybutyric acid. 
7. The composition of claim 1 or 2 or delivery device 
of claim 3 wherein the polymeric slab comprises a poly 
ester of biologically metabolizable monomeric units of 
lactic acid or glycolic acid. 
8. The composition of claim 1 or 2 or delivery device 
of claim3 wherein the polymeric slab comprises a poly 
amide. 
9. A composition of claim 1 or 2 or delivery device of 
claim 3 wherein the polymeric slab comprises a poly 
peptide. 
10. The composition of claim 1 or 2 or delivery de 
vice of claim 3 wherein the enzyme hydrolyses ester 
bonds and comprises a hydrolase or a protease. 
11. The composition of claim 1 or 2 or delivery de 
vice of claim 3 wherein the enzyme is selected from the 
group consisting of: 
proteinase K, bromelain, pronase E, cellulase, dex 
tranase, elastase, plasmid, streptokinase, trypsin, 
chymotrypsin, papain, chymopapain, collagenase, 
subtilisin, ficin, carboxypeptidase A, pectinase, and 
pectinesterase. 
12. The composition of claims 1 or 2 or delivery 
device of claim 3 wherein the enzyme is proteinase K, 
bromelain or pronase E. 
13. The compositions of claim 1 or 2 or delivery 
device of claim 3 wherein the enzyme is proteinase K. 
14. The compositions of claim 1 or 2 or delivery 
device of claim 3 wherein the enzyme is proteinase Kat 
a concentration of about 0.5% by weight of the poly 
meric slab. 
15. The device of claim 3 wherein the enzyme is 
dispersed on the side of the polymeric slab for contact 
with the dermal surface. 
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16. The delivery device of claim 3 wherein the means 
for holding the device in contact with a dermal surface 
is an adhesive, elastic band or bandaging tape. 
17. The compositions of claim 1 or 2 or delivery 
device of claim 3 wherein the therapeutic agent com 
prises chlorpheniramine maleate. 
18. A delivery device for the transdermal administra 
tion of a therapeutic agent, said device comprising: 













a non-polymer bound, homogeneously dispersed 
therapeutic agent physically entrapped in said po 
ly(DL-lactide) polymeric slab; 
proteinase K included with the slab, which degrades 
the polymeric slab in the presence of moisture to 
release the therapeutic agent; and 
a means for holding the device in dermal contact 
selected from the group consisting of: 
an adhesive; 
an elastic band; and 
a bandaging tape, 
wherein the therapeutic agent is released at a rate which 
is a function of the concentration of the enzyme within 
the slab. 
k it sk 
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERT FICATE OF CORRECTION 
PATENT NO. : 5,227,157 
DATED : July 13, 1993 
NVENTORS : McGinity et al. 
It is certified that error appears in the above-identified patent and that said Letters Patent 
is hereby corrected as shown below: 
Column 20, 
claim 6, line 31, between the number "2" and the word 
"delivery," insert --or 
At claim 11, column 20, line 53, delete the term "plasmid." 
and substitute therefore --plasmin--. 
Signed and Sealed this 
Third Day of May, 1994 
(a teen 
BRUCELEMAN 
Attesting Officer Commissioner of Patents and Trademarks 
  
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERT FICATE OF CORRECTION 
PATENT NO. : 5,227,157 
DATED : July 13, 1993 
NVENTORS : McGinity et al. 
It is certified that error appears in the above-identified patent and that said Letters Patent 
is hereby corrected as shown below: 
Column 20, 
claim 6, line 31, between the number "2" and the word 
"delivery," insert --or 
At claim 11, column 20, line 53, delete the term "plasmid." 
and substitute therefore --plasmin--. 
Signed and Sealed this 
Third Day of May, 1994 
(a teen 
BRUCELEMAN 
Attesting Officer Commissioner of Patents and Trademarks 
  
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERT FICATE OF CORRECTION 
PATENT NO. : 5,227,157 
DATED : July 13, 1993 
NVENTORS : McGinity et al. 
It is certified that error appears in the above-identified patent and that said Letters Patent 
is hereby corrected as shown below: 
Column 20, 
claim 6, line 31, between the number "2" and the word 
"delivery," insert --or 
At claim 11, column 20, line 53, delete the term "plasmid." 
and substitute therefore --plasmin--. 
Signed and Sealed this 
Third Day of May, 1994 
(a teen 
BRUCELEMAN 
Attesting Officer Commissioner of Patents and Trademarks 
  
